Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-23T16:24:29.286Z Has data issue: false hasContentIssue false

Presence and evolution of a new psychoactive tryptamines branch

Published online by Cambridge University Press:  23 March 2020

Á. Palma Conesa*
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain
L. Galindo Guarin
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain
M. Grifell Guardia
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain
P. Quintana Mathe
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
C. Gil Lladanosa
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
I. Fornís Espinosa
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
M. Ventura Vilamala
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
M. Torrens Melich
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain
M. Farré Albaladejo
Affiliation:
Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain Servei de Farmacología Clínica, Hospital Germans Trías i Pujol, Clinical Farmacology, Barcelona, Spain
M.F. Fonseca Casals
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

New psychoactive substances (NPS) are substances that have recently appeared on the market and are not under international control. NPS use is experiencing an unprecedented increase. DiPT, 4-HO-DiPT and 4-AcO-DiPT are new psychoactive tryptamines and their effects may differ from those of other psychoactive tryptamines.

Objective

To explore the presence of DiPT, 4-HO-DiPT and 4-AcO-DiPT from samples delivered to and analyzed by Spanish harm reduction service Energy Control.

Materials and methods

All samples analyzed from 2009 to 2014 delivered as DiPT, 4-HO-DiPT and 4-AcO-DPT or containing these substances. Analysis was performed by gas chromatography–mass spectrometry.

Results

From 17,432 samples, 4-HO-DiPT was found in 16, delivered as 4-HO-DiPT (6); 4-AcO-DiPT (7); DiPT (1); 4-AcO-DMT (1) and cocaine (1). 4-AcO-DiPT was found in 16, delivered as 4-AcO-DiPT (12); 5-MeO-DMT (1); 5-MeO-DiPT (1); 4-AcO-DMT (1) and cocaine (1). Only 4 samples contained DiPT, all presented as DiPT. Nine samples contained both 4-AcO-DiPT and 4-HO-DiPT. During the years of study, 4-HO-DiPT deliverance was increasing (4 samples in 2014) while deliverance of 4-AcO-DiPT and DiPT was decreasing (1 sample in 2014).

Conclusions

Increasing 4-HO-DiPT presence could translate a progressive replacement of 4-AcO-DiPT and DiPT recreational use. Clinical relevance comes from its growing use and the absence of scientific evidence on humans, therefore relying on users subjective experience to predict the effects.

Disclosure of interest

The authors declare that they have no competing interest.

Type
EW13
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.